A new population-based study from Spain reveals that nearly 23% of people infected with COVID-19 between 2021 and 2023 went ...
MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.
Hosted on MSN14d
New antibody reduces tumor growth in tough-to-treat breast and ovarian cancers: StudyHER2 is responsible for cancer growth and is the target of existing therapies, such as the most commonly used type of antibodies, IgG. However, this treatment is not always effective in some patients.
Recent study conducted by Caushi et al. aimed to evaluate the role of Elisa IgG serum antibody titres in diagnosing pulmonary ...
An antibody discovery platform revealed more than 60 monoclonal antibodies specific to patients with alpha-gal syndrome, ...
Identifying antibodies for 75% of norovirus outbreaks, University researchers took a step forward in creating a vaccine for ...
Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate (ADC) linker platform.
The following is a summary of “Kinetics of tick-borne encephalitis virus IgM antibody responses in serum and cerebrospinal ...
The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback